Sensyne Health signs milestone agreement with Bayer

British clinical AI tech company Sensyne Health has signed a collaboration agreement with Bayer - its first major drug development agreement since IPO.  The initial two-year agreement, worth £5m to Sensyne, will see the AIM-listed start-up work with Bayer to accelerate the clinical development of new treatments for cardiovascular disease using its clinical AI technology platform. The collaboration with Bayer is a significant milestone for Sensyne Health that will underpin its growth over the next couple of years and has potential for further expansion. 

Oxford-based Sensyne IPO’d last August (see Sensyne raises £60m through IPO) and is in scale-up mode - in its first six months as a public company it made an operating loss of £5.1m on revenues of £39k. It is not your usual scale-up, however, and is definitely ‘one to watch’ in UK healthcare.  More...

Posted by: Tola Sargeant at 08:57

Tags: startup   health   AI   scaleup  

Add a comment